Comparison of High Performance Liquid Chromatography and Immunoassay Methods for Measurement of Cyclosporine A Blood Concentrations After Feline Kidney Transplantation

1998 ◽  
Vol 27 (6) ◽  
pp. 589-595 ◽  
Author(s):  
JONATHAN F. McANULTY ◽  
GARY L. LENSMEYER
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Kidney Transplantation ◽  
Cyclosporine A ◽  
High Performance ◽  
Blood Concentrations

scholarly journals Determination of Tissue Distribution of Alisol G, a CB1R Antagonist, in Rats by Ultra-High-Performance Liquid Chromatography-Tandem Mass Spectrometry

2021 ◽  
Author(s):  
Chen-Yu Gao ◽  
Jian-Qiang Xi ◽  
Ding-Zhong Song ◽  
Jie Yuan ◽  
Wu-Si Hao ◽  
...  
Keyword(s):  
Mass Spectrometry ◽  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Tandem Mass Spectrometry ◽  
High Performance ◽  
Tandem Mass ◽  
Blood Concentrations ◽  
Therapeutic Benefits ◽  
Chromatography Tandem Mass Spectrometry ◽  
Liquid Chromatography Tandem Mass

AbstractPeripheral CB1R blockers without crossing the blood–brain barrier (BBB) have demonstrated therapeutic benefits in metabolic syndromes, including obesity. Among them is Alisol G, a tetracyclic triterpene from Alismatis rhizoma (zexie), which can effectively reduce the weight of obese mice. Results from CP55940-induced [35S] GTPγS cannabinoid-type 1 receptor (CB1R) binding assay show an IC50 of 34.8 μmol/L for Alisol G, implicating its role as a CB1R antagonist. The purpose of our study is to assess whether Alisol G could serve as a peripheral CB1R antagonist for obesity treatment. In this study, we build a simple, reliable, and sensitive method to detect the concentration of Alisol G in rat tissue by ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The results showed that Alisol G was mainly distributed in intestinal midgut, mucosa and small intestine, with little brain exposure. We suggested that intestine may be the main acting sites of Alisol G. Through comparison of brain and blood concentrations of Alisol G, our data showed that Alisol G cannot penetrate the BBB easily. In conclusion, Alisol G may represent a peripheral CB1R antagonist for the further treatment of obesity.

Determination of Cyclosporine A by High-Performance Liquid Chromatography with Aryl Oxalate Chemiluminescence Detection

1998 ◽  
Vol 31 (4) ◽  
pp. 621-629 ◽  
Author(s):  
Masatoki Katayama ◽  
Hirokazu Taniguchi ◽  
Yoshifumi Matsuda ◽  
Sumiyuki Akihama ◽  
Satoru Kaneko ◽  
...  
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Cyclosporine A ◽  
High Performance ◽  
Chemiluminescence Detection

Quantification of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in serum using an isotope dilution UHPLC-MS/MS method with semi-automated sample preparation

2015 ◽  
Vol 53 (5) ◽  
Author(s):  
Johannes Zander ◽  
Barbara Maier ◽  
Anna Suhr ◽  
Michael Zoller ◽  
Lorenz Frey ◽  
...  
Keyword(s):  
High Performance Liquid Chromatography ◽  
Liquid Chromatography ◽  
Sample Preparation ◽  
High Performance ◽  
Matrix Effects ◽  
Chemical Properties ◽  
Sample Volume ◽  
Therapeutic Drug ◽  
Blood Concentrations ◽  
Carry Over

AbstractRecent studies have demonstrated highly variable blood concentrations of piperacillin, tazobactam, cefepime, meropenem, ciprofloxacin and linezolid in critically ill patients with a high incidence of sub-therapeutic levels. Consequently, therapeutic drug monitoring (TDM) of these antibiotics has to be considered, requiring robust and reliable routine analytical methods. The aim of the present work was to develop and validate a multi-analyte ultra high performance liquid chromatography tandem mass spectrometry (UHPLC-MS/MS) method for the simultaneous quantification of the above mentioned antibiotics.Sample preparation included a manual protein precipitation step followed by two-dimensional ultra high performance liquid chromatography (2D-UHPLC). Corresponding stable isotope-labeled substances were used as internal standards for all of the analytes, with the exception of tazobactam. The injected sample volume was 7 μL. The run time was 5.0 min.Inaccuracy was ≤8% and imprecision coefficient of variation (CV) was <9% for all analytes. Only minor matrix effects and negligible carry-over was observed. The method was found to be robust during the validation period.We were able to develop a reliable 2D-UHPLC-MS/MS method addressing analytes with highly heterogeneous physico-chemical properties. The novel assay may be an efficient tool for an optimized process workflow in clinical laboratories for important antibiotics in regards to TDM.

Sign in / Sign up

Export Citation Format

Share Document